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Ancestry	  Ma?ers!	  -­‐	  Ogden	  Syndrome	  	  
The	  muta*on	  in	  NAA10	  is	  necessary,	  but	  we	  do	  not	  know	  if	  it	  is	  sufficient	  to	  cause	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  in	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  gene*c	  background.	  It	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  “contributes	  to”	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  machinery	  (NatA)	  in	  
human	  cells.	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  Major	  Features	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Summary
Background The genetic cause of intellectual disability in most patients is unclear because of the absence of 
morphological clues, information about the position of such genes, and suitable screening methods. Our aim was to 
identify de-novo variants in individuals with sporadic non-syndromic intellectual disability.
Methods In this study, we enrolled children with intellectual disability and their parents from ten centres in Germany 
and Switzerland. We compared exome sequences between patients and their parents to identify de-novo variants. 
20 children and their parents from the KORA Augsburg Diabetes Family Study were investigated as controls.
Findings We enrolled 51 participants from the German Mental Retardation Network. 45 (88%) participants in the 
case group and 14 (70%) in the control group had de-novo variants. We identifi ed 87 de-novo variants in the case 
group, with an exomic mutation rate of 1·71 per individual per generation. In the control group we identifi ed 
24 de-novo variants, which is 1·2 events per individual per generation. More participants in the case group had 
loss-of-function variants than in the control group (20/51 vs 2/20; p=0·022), suggesting their contribution to 
disease development. 16 patients carried de-novo variants in known intellectual disability genes with three 
recurrently mutated genes (STXBP1, SYNGAP1, and SCN2A). We deemed at least six loss-of-function mutations in 
six novel genes to be disease causing. We also identifi ed several missense alterations with potential pathogenicity.
Interpretation After exclusion of copy-number variants, de-novo point mutations and small indels are associated 
with severe, sporadic non-syndromic intellectual disability, accounting for 45–55% of patients with high locus 
heterogeneity. Autosomal recessive inheritance seems to contribute little in the outbred population investigated. 
The large number of de-novo variants in known intellectual disability genes is only partially attributable to known 
non-specifi c phenotypes. Several patients did not meet the expected syndromic manifestation, suggesting a strong 
bias in present clinical syndrome descriptions.
Funding German Ministry of Education and Research, European Commission 7th Framework Program, and Swiss 
National Science Foundation.
Introduction
Intellectual disability is defi ned as substantial impair-
ment of cognitive and adaptive functions that has onset in 
childhood1 and has an estimated prevalence of 1·5–2·0%.2 
Whereas frequency estimates of mild intellectual dis-
ability diff er between studies, most researchers agree that 
severe intellectual disability (an intelligence quotient of 
<50) has a prevalence of 0·3–0·4%.2 Studies of genetic 
changes in children with intellectual disability have led to 
the identifi cation of mutations in many genes on the 
X chromosome3 and some genes on autosomal chromo-
somes.4,5 However, the genetic basis of the disorder is still 
unclear in most aff ected children, especially those with 
non-syndromic intellectual disability, in whom there are 
no physical signs.6 The diffi  culty of establishing the 
genetics of intellectual disability could be because of the 
high locus heterogeneity and—for autosomal dominant 
inheritance—the large reproductive disadvantage of the 
disease, which hampers use of linkage analysis and 
subsequent positional cloning. The introduction of array-
based copy-number analysis led to the identifi cation of 
de-novo microdeletions and duplications present in 
several genes in roughly 14% of patients with intellectual 
disability.7 Sequencing of candidate genes and use of next-
generation sequencing techniques showed that a large 
proportion of sporadic cases might be caused by de-novo 
point mutations and small insertions or deletions.4,8 Our 
aim was to identify de-novo variants by exome sequencing 
in patients with intellectual disability.
Methods
Study design and patients
Between February and November, 2011, we enrolled 
patients with  severe non-syndromic intellectual disability 
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Intellectual disability is defi ned as substantial impair-
ment of cognitive and adaptive functions that has onset in 
childhood1 and has an estimated prevalence of 1·5–2·0%.2 
Whereas frequency estimates of mild intellectual dis-
ability diff er between studies, most researchers agree that 
severe intellectual disability (an intelligence quotient of 
<50) has a prevalence of 0·3–0·4%.2 Studies of genetic 
changes in children with intellectual disability have led to 
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based copy-number analysis led to the identifi cation of 
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Sex Gene Online 
Mendelian 
Inheritance 
in Man 
reference
Type Genomic change Protein change Haploinsuffi  ciency 
index (%)
PolyPhen2 category 
(score)
E10-0275 Male IQSEC2 309530 Nonsense X chromosome: g.53277315G→A Arg855*1 9·8% ··
BO17/09 Female MECP2 312750 Frameshift X chromosome: g.153296093_153296115del Pro401Argfs*8 24·3% ··
ZH58769 Male NAA10 300855 Missense X chromosome: g.153197564G→A Arg116Trp ·· Benign (0·233)*
ER52725 Female SATB2 608148 Missense Chromosome 2: g.200213455A→C Val381Gly 4·3% Probably damaging (1)
ER8490 Male SCN2A 613721 Frameshift Chromosome 2: 
g.166179821_166179822delCT
Leu611Valfs*35 12·7% ··
MS111684 Male SCN2A 613721 Frameshift Chromosome 2: g.166172100_166172101insA Asn503Lysfs*19 12·7% ··
ZH60991 Femal SCN2A 613721 Missense Chromosome 2: g.166201311C→T Arg937Cys 12·7% Probably damaging (1)
ER12988 Female SCN8A 614558, 
614306
Missense Chromosome 12: g.52200120G→A Arg1617Gln 14·5% Probably damaging (1)
BO22/10 Female SETBP1 269150 Nonsense Chromosome 18: g.42531079A→T Lys592* 9·9% ··
PL111540 Male SLC2A1 606777, 
612126
Missense Chromosome 1: g.43396356G→A Arg153Cys 24·1% Probably damaging (1)
ES07E0046 Female STXBP1 612164 Missense Chromosome 9: g.130422363G→C Ala101Pro 8·7% Possibly damaging 
(0·860)†
MR-NET001 Female STXBP1 612164 Splice Chromosome 9: g.130422308delC Aberrant splicing 
predicted
8·7% ··
P4276 Female STXBP1 612164 Missense Chromosome 9: g.130420659G→A Glu59Lys 8·7% Probably damaging 
(0·994)
BO14/09 Female SYNGAP1 612621 Frameshift Chromosome 6: g.33410958_33410959insT Thr878Aspfs*60 23·6% ··
ER53899 M le SYNGAP1 612621 Frameshift Chromosome 6: g.33405934_33405935delAA Lys418Argfs*54 23·6% ··
TUBA080997 Female TCF4 610954 Missense Chromosome 18: g.53070725G→A Ser110Leu 1·9% Benign (0·073)
*Molecular modelling suggests that the bulky Trp116 side-chain interferes with coenzyme A binding, thereby aff ecting enzymatic activity. †The crystal structure indicates that Ala101 is located at the N-terminal 
region of a sheet struc ure. The φ angl  of –158° is not possible for proline, and molecular modelling suggests that this mutation destabilises the structure and probably also hampers ligand binding (appendix). 
Table 3: Missense, nonsense, frameshift, and splice site de-novo variants in genes associated with intellectual disability in each patient–parent trio
Figure 2: Comparisons of probability of haploin uffi  ciency (A) and phyloP score (B) between cases, controls, and exome averag
The probabilities of haploinsuffi  ciency (n=17 070) and the phyloP scores (n=19 592) of most genes in the exome were compared with the scores of genes carrying 
de-novo variants in cases and controls. The genes in the case group were further subdivided into genes known to be associated with intellectual disability, novel 
genes with loss-of-function variants (nonsense, splice site, and frameshift mutations) and novel genes with missense variants. We calculated phyloP scores for entire 
genes as the average of all single nucleotides. The whiskers extend to the most extreme datapoint that is no more than 1·5-times the IQR from the box. Circles are 
single values of the corresponding genes.
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Supplementary Table S1. Clinical features
Patient ID Current 
speech
Behavioural anomalies Seizures Age of 
onset 
(seizures) 
[mo]
MRI (at age [mo]) Minor anomalies Others Age of 
mother at 
birth [y]
Age of 
father 
at birth 
[y]
Diagnostic tests before 
exome (besides 
karyotype, array, FMR1)
X11763 single words - multifocal 36
pinealis cyst, narrow 
corpus callosum [40]
acc. nipples, clinodact. V, syndact. toes 
II/III
ataxia, 
hypotonia
30 37 MECP2, AS
ZH50527 - finger flapping
myoclonic-astatic, 
atyp. absences
60
delayed myelination 
[39]
large nose, long columella, full lips, 
diasthema, finger pads
dystonia, 
hypotonia
27 39 AS, TCF4, mat. X-inact.
ZH50743
simple 
sentences
repetitive behavior, 
aggressive, short 
attent. span
myoclonic-astatic 66
mild cerebellar 
atrophy [60]
flat, long face, large upper incisors, 
prognathism
- 34 38 AS
ZH58769 -
hyperactivity, hand 
biting
- -
enlarged ventricles, 
reduced 
periventricular 
volume, gliotic 
changes [66]
large ears, small hands/ feet, dias-
thema, high palate
truncal 
hypotonia, 
hypertonia 
of extrem.
32 36 AS, mat. X-inact.
ZH60991
simple 
sentences
ASD, hyperventilation, 
aggressive
- / - myopia, chronic obstipation - 31 35 -
ZH61135 - - one single seizure 18 -
cryptorchidism, strabism, small 
mouth, thin upper lip, synophrys
hypotonia 33 34
ARX, VPS13B, mat. X-
inactivation
ZH64035 - ASD - / -
high forehead, large ears, thin upper 
lip, atyp. transverse crease
- 36 37 mat. X-inactivation
g: gram, SD: standard deviation, y: years, OFC: occipitofrontal circumference, mo: months, IUGR: intrauterine growth retardation, m: male, f: female, n.r.: not reported, pat: paternal, CHD: congenital heart defect
mat: maternal, ASD: autism spectrum disorder, VSD: ventricular septal defect
Supplementary Table S1. Clinical features
Patient ID Family history Gender Ethnicity Prenatal 
anomalies
Weeks of 
gestation
Birth weight 
[g/SD]
OFC at birth 
[cm/SD]
Age at last 
investi-
gation [y]
Height 
[cm/SD]
OFC [cm/SD] IQ Sitting 
age [mo]
Walking 
age [mo]
Age at first 
words [mo]
X11763 uneventful f German early bleedings 38 3040/-0·32 35/0·54 7      120/-0·44 50/-1·21 <50 n.r. 22 13
ZH50527 uneventful m Swiss - 39 3770/0·66 n.r. 8 11/12 138·2/0·46 53·5/0·29 30 10 26 -
ZH50743 uneventful f Italian - 36 2900/0·08 n.r. 12 147·6/-0·32 52·6/-0·72 <50 n.r. 26 48
ZH58769 distantly ID m Swiss - 41 3500/-0·53 n.r. 5 11/12 108/-1·92 50/-1·7 <20 18 / /
ZH60991 un ventful f Swiss n.r. 41 3800/0·14 n.r. 18  1/3 155/-2·5 55/-1·07 <50 24 24 24
ZH61135
distantly ID and 
transv. red. defect
m Greek - 38 3570/0·6 35·5/0·43 3  2/3 101/-0·9 52/0·4 50-60 42 - -
ZH64035 uneventful m Swiss
increased 
movements
39 3630/0·33 35/-0·23 3  1/6 94·5/-0·69 51·2/0·28 50-60 10 16 -
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“Although	  two	  variants	  were	  classified	  as	  benign,	  the	  
phenotypic	  features	  of	  the	  affected	  pa*ent	  and	  predic*ons	  
based	  on	  protein	  structure	  suggest	  that	  the	  NAA10	  variant	  has	  
a	  causal	  effect	  (appendix).”	  
	  
“The	  children	  in	  our	  study	  did	  not	  have	  cardiac	  anomalies	  
associated	  with	  Ogden	  syndrome,	  the	  typical	  facial	  features	  of	  
PiV-­‐Hopkins	  syndrome,	  or	  the	  ataxia	  described	  in	  children	  with	  
SCN8A	  muta*ons.”	  
	  
“The	  R116W	  muta*on	  of	  NAA10	  is	  located	  in	  the	  
acetyltransferase	  domain,	  which	  was	  modeled	  using	  the	  
structure	  of	  the	  homologous	  ARD1	  acetylase	  domain	  from	  
Sulfolobus	  as	  template	  (PDB	  code:	  2X7B).”	  
	  
C)	  Loca*on	  of	  R116	  (green)	  in	  the	  acetyltransferase	  
domain	  (cyan)	  of	  NAA10.	  The	  cofactor	  coenzyme	  A	  
(CoA)	  is	  shown	  in	  space-­‐filled	  presenta*on	  and	  colored	  
according	  to	  the	  atom	  type.	  D)	  In	  the	  R116W	  mutant,	  
W116	  preferen*ally	  adopts	  a	  sidechain	  orienta*on	  
that	  interferes	  with	  CoA	  binding.	  The	  steric	  clashes	  
between	  W116	  and	  CoA	  are	  indicated	  by	  a	  red	  arrow.	  
These	  clashes	  are	  expected	  to	  hamper	  CoA	  binding	  and	  
to	  reduce	  the	  enzyma*c	  ac*vity.	  
Supplementary Figure S2 
 
 
 
Supplementary Figure S2. Protein structure-based predictions. 
A) Location and interactions of E59 and A101 in STXPB1 (blue). E59 forms tight electrostatic 
interactions (green lines) with R114 of Syntaxin-1A (cyan) in the complex crystal structure (PDB 
code: 3C98). A101 is located at the N-terminus of a beta-strand and adopts a phi-angle of -158° 
that is sterically impossible for proline. 
B) The E59K mutation leads to a loss of the intermolecular interaction with R114 due to 
electrostatic repulsion between the two positively charged residues. The A101P mutation leads to 
a destabilization of the structure and causes a rearrangement of the adjacent turns (red arrows), 
which is likely to affect also syntaxin binding. 
C) Location of R116 (green) in the acetyltransferase domain (cyan) of NAA10. The cofactor 
coenzyme A (CoA) is shown in space-filled presentation and colored according to the atom type. 
D) In the R116W mutant, W116 preferentially adopts a sidechain orientation that interferes with 
CoA binding. The steric clashes between W116 and CoA are indicated by a red arrow. These 
clashes are expected to hamper CoA binding and to reduce the enzymatic activity. 
E) Location and interactions of Q264 in DEAF1. DEAF1 is shown in backbone presentation and 
colored according to the secondary structure type. The backbone amide group of Q264 forms a 
hydrogen bond with K253 (green line), which is part of the DNA-binding interface of DEAF1. 
F) Due to the lack of an amide proton, the respective hydrogen bond cannot be formed in the 
Q264P mutant, which is expected to cause destabilization of the DEAF1 structure and also to 
affect its DNA binding properties. 
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New population-based exome data are questioning the
pathogenicity of previously cardiomyopathy-associated
genetic variants
Charlotte Andreasen1,2,5, Jonas B Nielsen1,2,5, Lena Refsgaard1,2, Anders G Holst1,2, Alex H Christensen1,2,
Laura Andreasen1,2, Ahmad Sajadieh3, Stig Haunsø1,2,4, Jesper H Svendsen1,2,4 and Morten S Olesen*,1,2
Cardiomyopathies are a heterogeneous group of diseases with various etiologies. We focused on three genetically determined
cardiomyopathies: hypertrophic (HCM), dilated (DCM), and arrhythmogenic right ventricular cardiomyopathy (ARVC). Eighty-four
genes have so far been associated with these cardiomyopathies, but the disease-causing effect of reported variants is often
dubious. In order to identify possible false-positive variants, we investigated the prevalence of previously reported
cardiomyopathy-associated variants in recently published exome data. We searched for reported missense and nonsense variants
in the NHLBI-Go Exome Sequencing Project (ESP) containing exome data from 6500 individuals. In ESP, we identified 94
variants out of 687 (14%) variants previously associated with HCM, 58 out of 337 (17%) variants associated with DCM, and
38 variants out of 209 (18%) associated with ARVC. These findings correspond to a genotype prevalence of 1:4 for HCM, 1:6
for DCM, and 1:5 for ARVC. PolyPhen-2 predictions were conducted on all previously published cardiomyopathy-associated
missense variants. We found significant overrepresentation of variants predicted as being benign among those present in ESP
compared with the ones not present. In order to validate our findings, seven variants associated with cardiomyopathy were
genotyped in a control population and this revealed frequencies comparable with the ones found in ESP. In conclusion, we
identified genotype prevalences up to more than one thousand times higher than expected from the phenotype prevalences in
the general population (HCM 1:500, DCM 1:2500, and ARVC 1:5000) and our data suggest that a high number of these
variants are not monogenic causes of cardiomyopathy.
European Journal of Human Genetics advance online publication, 9 January 2013; doi:10.1038/ejhg.2012.283
Keywords: cardiomyopathy; exome; next-generation sequencing; HCM; DCM; ARVC
INTRODUCTION
Cardiomyopathy is a diverse group of cardiac disorders characterized
by mechanical and/or electrical dysfunction of the cardiac muscle.
The diseases are associated with significant morbidity and mortality
and are a known risk factor for sudden cardiac death.1–3 Over time,
several classification systems have evolved based on etiology, anatomy,
physiology, or histopathological expression.4 In newer classification
systems, major types include hypertrophic cardiomyopathy (HCM),
dilated cardiomyopathy (DCM), and arrhythmogenic right
ventricular cardiomyopathy (ARVC).
Hypertrophic cardiomyopathy is characterized by a non-dilated,
hypertrophic left ventricle with variable degrees of diastolic dysfunc-
tion, whereas DCM is characterized by dilated ventricular cavities and
systolic dysfunction.4–7 In ARVC, progressive fibrofatty replacement
of the normal cardiac tissue predisposes to ventricular tachycardia and
sudden death.8,9 The prevalence of these three cardiomyopathies in
the general population has been estimated to be 1:500, 1:2500, and
1:5000, respectively.3
Inherited cardiomyopathy has traditionally been considered a
monogenic disorder and to date hundreds of variants in 84 genes
have been associated with these syndromes. However, some associa-
tions are based on weak family phenotype–genotype co-segregation
and/or the absence of the variant in a limited number of controls.
Until recently, there has only been limited knowledge regarding the
genetic variation in the general population, especially with regard to
low-frequency variants. This was changed in June 2011 when whole
exome data from the NHLBI GO Exome Sequencing Project (ESP) was
published (latest update June 2012).10 In order to identify possible
false-positive cardiomyopathy variants reported in the literature, we
aimed to investigate the prevalence of previously cardiomyopathy-
associated variants in the new ESP exome data and compare the
prevalence of these variants with the expected prevalences of
monogenic cardiomyopathies in the same population.
METHODS
In ESP, next-generation sequencing of all protein coding regions in 6500
individuals, including both European Americans (4300 individuals) and
African Americans (2203 individuals), from different population studies were
carried out.10 No clinical data were available on the ESP population, nor at
request. By literature search, we found inclusion and exclusion criteria on 9/12
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Likely	  X-­‐linked	  or	  Autosomal	  Recessive,	  with	  X-­‐linked	  being	  supported	  by	  extreme	  X-­‐
skewing	  in	  the	  mother	  	  
New	  Syndrome	  with	  Dysmorphology,	  Severe	  
Intellectual	  Disability,	  “Au*sm”,	  “ADHD”	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  gene*c	  tests	  nega*ve,	  including	  nega*ve	  for	  
Fragile	  X	  and	  many	  candidate	  genes.	  
•  No	  obvious	  pathogenic	  CNVs	  –	  several	  microarrays	  
without	  any	  defini*ve	  result.	  
•  Sequenced	  whole	  genomes	  of	  Mother,	  Father	  and	  Two	  
Boys,	  using	  Complete	  Genomics,	  obtained	  data	  in	  June	  
of	  this	  year,	  i.e.	  version	  2.0	  CG	  pipeline.	  
Jason	  O’Rawe	  
Complete	  Genomics	  chemistry	  -­‐	  combinatorial	  
probe	  anchor	  liga*on	  (cPAL)	  
•  No	  obvious	  pathogenic	  CNVs	  in	  both	  brothers.	  
•  No	  autosomal	  recessive	  SNVs	  or	  indels	  in	  
protein-­‐coding	  regions	  in	  both	  brothers.	  
•  One	  puta*ve	  interes*ng	  homozygous	  de	  novo	  
muta*on	  in	  both	  brothers,	  but	  valida*ng	  now	  
with	  Sanger	  sequencing.	  The	  mechanism	  of	  
this	  is	  uncertain?	  
Analysis	  with	  VAAST,	  ANNOVAR,	  and	  Golden	  Helix	  SVS	  
22,174	  
272	  
56	  
7	  
6	  
5	  
3	  
SIFT	  classifica*on	  
Variant	  classifica*on	  
VAAST	  score	  
Chromosome	   Posi*on	   Reference	   Coding?	   SIFT	  Score	   Score	  <=	  0.05	   Ref/Alt	  Alleles	  
X	   47307978	   G	   YES	   0.649999976	   0	   G/T	  
X	   63444792	   C	   YES	   0	   1	   C/A	  
X	   70621541	   T	   YES	   0.009999999776	   1	   T/C	  
Variant	   Reference	   Alternate	   Classifica*on	   Gene	  1	   Transcript	  1	   Exon	  1	   HGVS	  Coding	  1	   HGVS	  Protein	  1	  
X:47307978-­‐SNV	   G	   T	   Nonsyn	  SNV	   ZNF41	   NM_007130	   5	  c.1191C>A	   p.Asp397Glu	  
X:63444792-­‐SNV	   C	   A	   Nonsyn	  SNV	   ASB12	   NM_130388	   2	  c.739G>T	   p.Gly247Cys	  
X:70621541-­‐SNV	   T	   C	   Nonsyn	  SNV	   TAF1	   NM_004606	   25	  c.4010T>C	   p.Ile1337Thr	  
RANK	   Gene	   p-­‐value	   p-­‐value-­‐ci	   Score	   Variants	  
1	   ASB12	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   38.63056297	   chrX:63444792;38.63;C-­‐>A;G-­‐>C;0,3	  
2	   TAF1	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   34.51696816	   chrX:70621541;34.52;T-­‐>C;I-­‐>T;0,3	  
3	   ZNF41	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   32.83011803	   chrX:47307978;32.83;G-­‐>T;D-­‐>E;0,3	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Mutations in the ZNF41 Gene Are Associated with Cognitive Deficits:
Identification of a New Candidate for X-Linked Mental Retardation
Sarah A. Shoichet,1 Kirsten Hoffmann,1 Corinna Menzel,1 Udo Trautmann,2 Bettina Moser,1
Maria Hoeltzenbein,1 Bernard Echenne,3 Michael Partington,4 Hans van Bokhoven,5
Claude Moraine,6 Jean-Pierre Fryns,7 Jamel Chelly,8 Hans-Dieter Rott,2 Hans-Hilger Ropers,1
and Vera M. Kalscheuer1
1Max-Planck-Institute for Molecular Genetics, Berlin; 2Institute of Human Genetics, University of Erlangen-Nuremberg, Erlangen-Nuremberg;
3Centre Hospitalier Universitaire de Montpellier, Hoˆpital Saint-Eloi, Montpellier, France, 4Hunter Genetics and University of Newcastle,
Waratah, Australia; 5Department of Human Genetics, University Medical Centre, Nijmegen, The Netherlands; 6Services
de Ge´ne´tique–INSERM U316, CHU Bretonneau, Tours, France; 7Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium;
and 8Institut Cochin de Ge´ne´tique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris
Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
Received July 22, 2003; accepted for publication September 25, 2003;
electronically published November 18, 2003.
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
Am. J. Hum. Gen t. 73:1341–1354, 2003
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specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
Received July 22, 2003; accepted for publication September 25, 2003;
electronically published November 18, 2003.
Address for correspondence and reprints: Dr. Vera Kalscheuer,Max-
Planck-Institute for Molecular Genetics, Ihnestrasse 73, D-14195Berlin,
Germany. E-mail: kalscheu@molgen.mpg.de
! 2003 by The American Society of Human Genetics. All rights reserved.
0002-9297/2003/7306-0013$15.00
linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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Figure 6 Northern blot hybridization of ZNF41, by use of a probe corresponding to nucleotides 621–1099 of ZNF41 transcript variant
1. A, Adult tissues (left to right): heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. B, Fetal tissues (left to right): brain,
lung, liver, and kidney.C,Adult brain structures (left to right): amygdala, caudate nucleus, corpus callosum, hippocampus, whole brain, substantia
nigra, and thalamus. Black arrowheads highlight the presence of a novel 6-kb transcript. Actin (A and C) or GAPDH (B) served as controls
for RNA loading.
sible for sequence-specific DNA binding. ZNF41, absent
in our patient, is a member of the subfamily of Krueppel-
type zinc-finger proteins harboring a highly conservedN-
terminal domain known as the Krueppel-associated box
(KRAB). Although the specific functions of ZNF41 are
not fully understood, various related genes play an es-
tablished and important role in human development and
disease (Ladomery and Dellaire 2002). In another female
patient with severe MRX and a balanced tra slocation,
the disorder probably esulted from t disruption of a
related X-chromosomal zinc-fing r gene (Lossi et al.
2002). The X-chromosome breakpoint was located just
upstream of the Krueppel-like factor 8 (KLF8 [MIM
300286]), also k own as the “ZNF741 gene,” and it was
confirmed that KLF8 transcripts were absent in the pa-
tient cell line. The Wilms tumor suppressor gene WT1
(MIM 194070), hich arbors four Krueppel-type zinc
fingers, has been implicated in several urogenital devel-
opmental disorders, including WAGR syndrome (MIM
194072), which is associated with MR (Call et al. 1990;
Rose et al. 1990; Gessler et al. 1992). Of particular rel-
evance, however, are the biochemical studies that high-
light the links betwee th highly conserved KRAB/ZFP
s bfamily of zinc-fing r proteins and chromatin remod-
eling. Many disorders, several of which are associated
with MR, have been linked to defects in processes that
govern chromatin structural modification (Hendrich and
Bickmore 2001), suggesting that chromatin structural
regula ionmay play a specific and important role in path-
ways critical for mental function.
Repression of transcription by a KRAB/ZFP requires
binding of the corepressor KAP-1 (also known as
“TIF1b” and “KRIP-1” [MIM 601742]) (Friedman et
al. 1996; Kim et al. 1996; Moosmann et al. 1996; Peng
et al. 2000a, 2000b). KAP-1 is a molecular scaffold that
coordinates gene-specific ilencing by recruiting both
heterochromatin-associated proteins (Ryan et al. 1999)
and by interacting with the novel histone H3 Lys9–
specific methyltransferase SETDB1 (MIM 604396)
(Schultz et al. 2002). It is interesting that, within the
primary sequence of SETDB1, Schultz et al. (2002) iden-
tified a methyl CpG–binding domain that is related to
the domain found in the methyl CpG binding protein
MeCP2, which is mutated both in patients with Rett
syndrome (MIM 312750) (Amir et al. 1999) and in
pati nts with MRX (Couvert et al. 2001; Yntema et al.
2002). Like ZNF41, MECP2 is ubiquitously expressed;
yet loss of functional protein results in a neurological
phenotype. Although the mechanism by whichMECP2
mutations cause MR is not clear, it is well established
that MeCP2 binds to methylated CpGs and represses
transcription (for review, see Ballestar and Wolffe
[2001]), and it has recently been shown that MeCP2
associates with an unidentified methyltransferase that
sp cifically methylates Lys9 of histone H3 (Fuks et al.
2003), as does the KAP-1/KRAB/ZFP binding partner
SETDB1.
Further characterization of the KRAB/KAP-1 repres-
sor module has indicated that, in addition to the KRAB
domain, a bipartite domain of the plant homeodomain
(PHD) finger and a bromodomain, located within the C-
terminal portion of KAP-1, are also required for effective
gene silencing (Schultz et al. 2002). It is interesting that
the point mutations in that study were modeled after
naturally occurring mutations in the PHD finger of the
human ATRX gene, which has been implicated in both
X-linked a-thalassemia/MR syndrome (MIM 301040)
(Gibbons et al. 1995) and Juberg-Marsidi syndrome
(MIM 309590), which is also associated with MR (Vil-
lard et al. 1996a). In light of the fact that the PHD
•  KRAB	  (Kruppel-­‐associated	  box)	  domain	  -­‐A	  box.	  
•  The	  KRAB	  domain	  is	  a	  transcrip*on	  repression	  module,	  found	  
in	  a	  subgroup	  of	  the	  zinc	  finger	  proteins	  (ZFPs)	  of	  the	  C2H2	  
family,	  KRAB-­‐ZFPs.	  KRAB-­‐ZFPs	  comprise	  the	  largest	  group	  of	  
transcrip*onal	  regulators	  in	  mammals,	  and	  are	  only	  found	  in	  
tetrapods.	  	  
•  The	  KRAB	  domain	  is	  a	  protein-­‐protein	  interac*on	  module	  
which	  represses	  transcrip*on	  through	  recrui*ng	  corepressors.	  
The	  KAP1/	  KRAB-­‐AFP	  complex	  in	  turn	  recruits	  the	  
heterochroma*n	  protein	  1	  (HP1)	  family,	  and	  other	  chroma*n	  
modula*ng	  proteins,	  leading	  to	  transcrip*onal	  repression	  
through	  heterochroma*n	  forma*on.	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Figure 4 A, Pedigree of family P13, with sequence corresponding to the prolinerleucinemutation (left to right): unrelated control individual,
mother (II:1), index patient (III:2), and brother of the index patient (III:1). For the potentially affected female cousin (individual III-4) (indicated
with an asterisk [*]), no clinical data are available. Affected nucleotides are indicated with black arrows. B, Pedigree for family P42, with
sequence chromatograms indicating the splice-site mutation in affected individuals (left to right): father (I:1), mother (I:2), index patient (II:1),
and mildly affected sister (II:2). Uppercase letters indicate coding sequence; affected nucleotides are indicated with black arrows.
a diagnosis of mild MR. He was born at term (by Ce-
sarean section), with a birth weight of 3,000 g (10th–25th
percentile) and a length of 51 cm (50th percentile). He
walked at age 12–13 mo and reached early milestones
within the normal time frame; however, he exhibited a
severe language delay. He first made two-word associa-
tions at age 3 years and was first speaking in simple
phrases at age 4 years 6 mo. At age 8 years, he was 135
cm tall (90th percentile) and had a head circumference
of 53 cm (75th percentile). He had no additional dys-
morphic or neurological symptoms, and results of
screening for fragile X were negative. At age 10 years 3
“The	  P111L	  change	  also	  found	  in	  two	  
"male	  controls"	  (EVS	  server,	  ESP6500).	  
	  
More	  recently,	  we	  have	  iden*fied	  this	  
change	  in	  another	  family	  with	  XLID.	  Co-­‐
segrega*on	  analysis	  in	  this	  family	  is	  in	  
progress.	  	  
	  
Furthermore,	  there	  are	  two	  rare,	  likely	  
heterozygous	  ZNF41	  frameshis	  
muta*ons	  and	  one	  heterozygous	  stop-­‐
gained	  muta*on	  reported	  in	  control	  
individuals	  (ESP6500).”	  
	  
	  
	  	  	  	  	  -­‐Personal	  communica.on,	  Vera	  Kalscheuer	  
?	  
	  
	  
	  
	  
	  
	  
	  
	  
X-­‐skewing	  
K10012-­‐10065	  
Het	  C/A	  
Het	  G/T	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
K10012-­‐10079	  
UNAFFECTED.	  
SNV	  A	  
SNV	  T	  
	  
No	  skewing	  
K10012-­‐10083	  
Het	  C/A	  
Het	  G/T	  
	  
K10012-­‐	  
10081	  
No	  skewing	  
Het	  C/A	  
Het	  G/T	  
	  
K10012-­‐	  
10084	  
w.t.	  C	  
w.t.	  G	  
	  
K10012-­‐	  
10080	  
w.t.	  C	  
w.t.	  G	  
	  
K10012-­‐10082	  
w.t.	  C	  
w.t.	  G	  
	  
K10012-­‐10068	  
w.t.	  C	  
w.t.	  G	  
	  
K10012-­‐	  
10066	  
SNV	  A	  
SNV	  T	  
	  
K10012-­‐	  
10067	  
SNV	  A	  
SNV	  T	  
	  
	  
Sanger	  validaEon:	  	  ASB12	  and	  ZNF41	  mutaEons	  
The	  muta*on	  in	  ZNF41	  may	  NOT	  be	  necessary,	  and	  it	  is	  certainly	  
NOT	  sufficient	  to	  cause	  the	  phenotype.	  
Proving	  Whether	  this	  MutaEon	  is	  Necessary	  and	  Sufficient	  
to	  result	  in	  the	  phenotype.	  
	  
•  Will	  need	  to	  find	  a	  second,	  unrelated	  family	  with	  same	  
exact	  muta*on	  and	  similar	  phenotype.	  
	  
•  Can	  also	  perform	  in	  vitro/in	  vivo	  studies	  and	  structural	  
modeling,	  and	  make	  knock-­‐in	  mice	  and/or	  test	  in	  
zebrafish,	  etc…	  for	  biological	  func*on.	  
•  What	  about	  the	  False	  Nega*ve	  Rate	  in	  Complete	  Genomes	  
data?	  What	  did	  we	  miss?	  
2-­‐3	  rounds	  of	  sequencing	  at	  BGI	  to	  a?ain	  
goal	  of	  >80%	  of	  target	  region	  at	  >20	  reads	  
per	  base	  pair	  
Exome Capture Statistics K24510-84060 K24510-92157-a K24510-84615 K24510-88962 
Target region (bp) 46,401,121  46,401,121  46,401,121  46,257,379  
Raw reads 138,779,950  161,898,170  156,985,870  104,423,704  
Raw data yield (Mb) 12,490  14,571  14,129  9,398  
Reads mapped to genome 110,160,277  135,603,094  135,087,576  83,942,646  
Reads mapped to target region 68,042,793  84,379,239  80,347,146  61,207,116  
Data mapped to target region (Mb) 5,337.69  6,647.18  6,280.01  4,614.47  
Mean depth of target region 115.03 143.25 135.34 99.76 
Coverage of target region (%) 0.9948  0.9947  0.9954  0.9828  
Average read length (bp) 89.91  89.92  89.95  89.75  
Fraction of target covered >=4X 98.17  98.38  98.47  94.25  
Fraction of target covered >=10X 95.18  95.90  95.97  87.90  
Fraction of target covered >=20X 90.12  91.62  91.75  80.70  
Fraction of target covered >=30X 84.98  87.42  87.67  74.69  
Capture specificity (%) 61.52  62.12  59.25  73.16  
Fraction of unique mapped bases on or near target 65.59  65.98  63.69  85.46  
Gender test result M M M F 
Depth	  of	  Coverage	  in	  15	  exomes	  >	  20	  
reads	  per	  bp	  in	  target	  region	  
>=1 >=10 >=20
Coverage depth
Fr
ac
tio
n 
of
 ta
rg
et
 co
ve
re
d 
(%
)
80
85
90
95
100
Pipelines	  Used	  on	  Same	  Set	  of	  Seq	  Data	  by	  Different	  
Analysts,	  using	  Hg19	  Reference	  Genome	  
1)  BWA	  -­‐	  GATK	  (version	  1.5)	  with	  recommended	  parameters	  	  (GATK	  IndelRealigner,	  
base	  quality	  scores	  were	  re-­‐calibrated	  by	  GATK	  Table	  Recalibra*on	  tool.	  
Genotypes	  called	  by	  GATK	  UnifiedGenotyper.	  For	  SNVs	  and	  indels.	  
	  
2)  BWA	  -­‐	  SamTools	  version	  0.1.18	  to	  generate	  genotype	  calls	  	  -­‐-­‐	  The	  “mpileup”	  
command	  in	  SamTools	  was	  used	  for	  iden*fy	  SNVs	  and	  indels.	  
	  
3)  SOAP-­‐Align	  –	  SOAPsnp	  for	  SNVs–	  and	  BWA-­‐SOAPindel	  (adopts	  local	  assembly	  
based	  on	  an	  extended	  de	  Bruijn	  graph)	  for	  indels.	  
	  
4)  GNUMAP-­‐SNP	  (probabilis*c	  Pair-­‐Hidden	  Markov	  which	  effec*vely	  accounts	  for	  
uncertainty	  in	  the	  read	  calls	  as	  well	  as	  read	  mapping	  in	  an	  unbiased	  fashion),	  for	  
SNVs	  only.	  
	  
5)  BWA	  -­‐	  Sam	  format	  to	  Bam	  format	  -­‐	  Picard	  to	  remove	  duplicates	  –	  SNVer	  ,	  for	  SNVs	  
only	  
Known	   Novel	  
All	  
Total	  mean	  overlap,	  plus	  or	  minus	  one	  standard	  deviaEon,	  observed	  between	  three	  
indel	  calling	  pipelines:	  GATK,	  SOAP-­‐indel,	  and	  SAMTools.	  	  a)	  Mean	  overlap	  when	  indel	  
posi*on	  was	  the	  only	  necessary	  agreement	  criterion.	  b)	  Mean	  overlap	  when	  indel	  
posi*on,	  base	  length	  and	  base	  composi*on	  were	  the	  necessary	  agreement	  criteria.	  	  	  
Indels-­‐	  Overlap	  by	  Base	  	  
Posi*on	  only	  
Indels-­‐	  Overlap	  by	  Base	  	  
Posi*on,	  Length	  and	  Composi*on	  
INDELS	  
•  How	  reliable	  are	  variants	  that	  are	  uniquely	  
called	  by	  individual	  pipelines?	  
•  Are	  some	  pipelines	  beVer	  at	  detec*ng	  rare,	  or	  
novel	  variants	  than	  others?	  
Cross	  valida*on	  using	  orthogonal	  
sequencing	  technology	  
	  (Complete	  Genomics)	  
Illumina	  SNVs	  
CG	  SNVs	  
Illumina	  indels	  
CG	  Indels	  
1698	  4364	  
2613	  
What	  is	  the	  “True”	  Personal	  Genome?	  
35653	   19407	  17322	  
2666	  
18331	   2085	  
915	  
50.5%	   32.2%	   17.3%	  
48.6%	   45.9%	   5.5%	  
Known	   Novel	  
All	  
Known	   Novel	  
GATK
GNUMAP
SAMTools
SNVer
SOAPsnp
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Personal	  genome	  “K8101”	  
All	  
Higher	  Valida*on	  of	  SNVs	  with	  the	  
BWA-­‐GATK	  pipeline	  
•  Reveals	  higher	  valida*on	  rate	  of	  unique-­‐to-­‐
pipeline	  variants,	  as	  well	  as	  uniquely	  
discovered	  novel	  variants,	  for	  the	  variants	  
called	  by	  BWA-­‐GATK,	  in	  comparison	  to	  the	  
other	  4	  pipelines	  (including	  SOAP).	  
Much	  Higher	  Valida*on	  of	  the	  Concordantly	  
Called	  Variants	  (by	  the	  CG	  data)	  
Valida*ng	  Indels	  with	  Complete	  
Genomics	  Data	  for	  the	  3	  pipelines	  

Conclusions	  
•  Ancestry,	  i.e.	  gene*c	  background,	  maVers!	  
•  We	  need	  to	  sequence	  whole	  genomes	  of	  large	  
pedigrees,	  and	  then	  construct	  super-­‐family	  
structures,	  star*ng	  in	  Utah.	  
•  Collec*vely,	  we	  need	  to	  improve	  the	  accuracy	  
of	  “whole”	  genomes,	  and	  also	  enable	  the	  
sharing	  of	  genotype	  and	  phenotype	  data	  
broadly,	  among	  researchers,	  the	  research	  
par*cipants	  and	  consumers.	  
Figure 4.	

	

Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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